SLCO1A2 and neoplasm: The accumulation in the tumor rather than in the CSF may be explained by a parallel efficient uptake transport, although it is reported, that ceritinib is not a substrate of breast cancer resistance protein (BCRP), organic cation transporter 1 (OCT1), organic anion transporter 2 (OAT2), or organic anion transporting polypeptide 1 (OATP1) [63].